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Aim: This study aimed to examine trends in prescribing of antidementia drugs
in primary care in England between 2009 and 2019, and investigate the impact
of deprivation, regional demography and disease prevalence on prescribing
practices.
Methods: Analysis of publicly available government data from various sources per-
taining to primary care prescribing and demographics was conducted. All primary care
prescription data pertaining to antidementia drugs in England between 2009 and
2019 were extracted and adjusted for inflation and population changes. Data across
English clinical commissioning regions were compared to explore the
association between prescribing trend, deprivation, regional demography and
dementia prevalence.
Results: The number of prescription items for antidementia drugs in England
increased by approximately 3-fold (195.4%) from 24 items/1000 population in 2009
to 70.9 items/1000 population in 2019. In 2019, the least-deprived areas had
approximately twice the rate of prescribing of antidementia drugs compared to the
most-deprived areas (median [IQR] values of 46.7 [36.6-64.8] vs 91.23 [76.2-95.1]
items/1000 population, respectively). In the multivariable analysis, the number of
prescription items showed an inverse relationship with deprivation (coefficient
−0.046, 95% CI −0.47 to −0.045) after adjustment for number of populations aged
65+ years and prevalence of dementia.
Conclusions: The 3-fold rise in the number of prescription items for antidementia
drugs in the study period reflects the policy emphasis on early diagnosis and
treatment of dementia. Higher rates of prescribing in the least-deprived areas may be
reflective of better and early diagnoses and access to treatments. Such inequality in
access to the treatments needs to be investigated further.
Principal investigator statement: The principal investigator for this study is Dr Vibhu Paudyal. This study involves analyses of publicly available government data from various sources pertaining
to primary care prescribing and demographics. Hence, participants were not subjected to intervention as part of the research.
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1 | INTRODUCTION
Globally, there are over 47 million people living with dementia, with
this figure set to reach 135.46 million by 2050.1 As of 2019, a total of
472 890 people in England have a coded diagnosis of dementia.2
The National Institute of Clinical Excellence (NICE) guideline on
Dementia in England recommends acetylcholinesterase (AChE) inhibi-
tors (donepezil, galantamine and rivastigmine) as monotherapies for
the management of mild-to-moderate Alzheimer's disease (AD).3 The
NICE guideline recommends that the N-methyl-D-aspartate (NMDA)
receptor antagonist, memantine, be used to treat moderate AD in
patients who are intolerant or have a contraindication to AChE inhibi-
tors. Memantine is also recommended to be used in patients with an
established diagnosis of AD when AChE inhibitors are already being
used. The NICE guidelines also recommend AChE inhibitors for the
treatment of non-Alzheimer's dementia, but they do not have UK
marketing authorisation for this purpose and therefore must be pre-
scribed off-label.3
In addition to AChE inhibitors and memantine, antipsychotics are
recommended for the management of noncognitive symptoms of
dementia. These symptoms of dementia include agitation, aggression,
distress and psychosis. In the UK, risperidone and haloperidol are the
only antipsychotics with a UK marketing authorisation to treat non-
cognitive symptoms associated with dementia.3
In the last decade, there has been an increased emphasis on the
diagnoses and management of dementia in primary care, prior to any
psychiatric referrals. The National Dementia Strategy (NDS), published
in 2009 in England, emphasised the need to improve public and pro-
fessional awareness and understanding of dementia and early diagno-
sis and treatment.4 The Quality and Outcomes Framework (QoF) is a
voluntary annual reward and incentive programme for all English gen-
eral practices. It incorporates better diagnosis and management of
dementia, including a follow-up care plan in primary care as one of the
key quality indicators.5
Evaluation of prescribing practices in dementia has predominantly
focused on minimising the potentially inappropriate use of antipsy-
chotics to treat noncognitive symptoms6–9 as overprescribing of anti-
psychotics can contribute to cardiovascular morbidity and mortality
mainly caused by stroke and ischaemic heart diseases; the drugs
therefore should only be prescribed where patients are severely dis-
tressed and there is a risk of harm to themselves or carers.10,11 A time
trend analysis of prescribing of drugs used in the management of
dementia is necessary in the context of recent policy emphases on
better diagnosis and management of dementia in primary care. In
addition, the link between deprivation, prevalence and prescribing for
dementia remains poorly understood. Geographical and deprivation
level variations in prescribing practices can inform stratification of
targeted interventions to identify linked comorbidities and reduce
health inequalities. The aim of this study was to analyse the trends in
prescribing of antidementia drugs in primary care in England from
2009 to 2019 and to investigate the impact of deprivation and
regional demography on prescribing practices.
2 | METHODS
2.1 | Ethical consideration
This study represents a secondary analysis of the information
retrieved from publicly available anonymised datasets and does not
warrant formal ethical approval.
2.2 | Study design and population
A longitudinal study of national primary care prescribing datasets was
undertaken using NHS Digital sources, namely, OpenPrescribing.net
What is already known about this subject
• There has been increasing policy emphasis on early diag-
noses and management of dementia in primary care.
• Evaluation of prescribing practices in dementia has
predominantly focused on minimising the potentially
inappropriate use of antipsychotics for the treatment of
noncognitive symptoms.
• The link between policy changes, prescribing practices,
deprivation and disease prevalence remains poorly
understood.
What this study adds
• In the last 10 years, there has been a nearly 3-fold rise
(195.4%) in the number of prescription items for
antidementia drugs, potentially reflecting the impact of
policy emphases on early diagnosis and treatment.
• Least-deprived areas demonstrate up to twice the rate of
prescriptions compared to most-deprived areas.
• Results indicate better and early diagnoses and access to
antidementia drugs in affluent areas compared to
deprived areas and this warrants further research.
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and Prescription Cost Analysis (PCA).12,13 OpenPrescribing.net is a
national online prescribing data resource hosted by the Evidence-
Based Medicine DataLab at the University of Oxford. The resource
provides general practice level prescribing data published each month
from NHS Digital for all prescriptions written by general practitioners
and other nonmedical prescribers attached to the practices. This
includes the number of items prescribed and the actual cost of the
medication.14 PCA statistics are provided by NHS Digital and present
prescription data regarding the number of items and the net ingredi-
ent cost (NIC) of all prescriptions dispensed by the NHS in the com-
munity in England.15
2.3 | Data extraction and analysis
Prescription data from January 2009 to December 2019 for
antidementia drugs, relating to British National Formulary (BNF)
Section 4.11,16 were included. Data on donepezil, galantamine,
rivastigmine and memantine were extracted. Prescription patterns
relating to 10 of the most- and the 10 of the least-deprived clinical
commissioning groups (CCGs) as per the Office of National Statistics
(ONS) Index of Multiple Deprivation (IMD) in 201517 (Supporting Infor-
mation Table S1) were also extracted and analysed to explore the link
between prescribing patterns and deprivation. The CCGs are clinically
led autonomous NHS bodies involved in planning and commissioning
healthcare services for their locality. The 10 most-deprived and the
10 least-deprived CCGs included in the analysis covered a population
of 2.8 million and 2.3 million, respectively. All data were adjusted for
population estimates for each year at national, regional and CCG
level.18 Costs of prescription items were adjusted for inflation using the
ONS Consumer Price Index (CPI) for pharmaceutical products.19
In the univariate analysis, the independent-samples Mann-
Whitney U test was used to examine prescription items' variations
and costs across deprivation. P values of <.05 were considered signifi-
cant. We used multivariable logistic regression to assess the associa-
tion of deprivation on prescription items after adjusting for population
aged 65+ years and prevalence of dementia. A frequency weight
was added into the model to denote that each row represented
aggregate data.
Trends in relation to prescribing of antipsychotic drugs from 2009
to 2019 from all English general practices were also extracted. Such
data included antipsychotic prescriptions for all causes. To identify
the extent of antipsychotic prescribing in patients with dementia, data
in relation to the proportion of patients with dementia who were pre-
scribed antipsychotic drugs in the last 6 weeks, including those with
or without a comorbid diagnosis of psychosis, were extracted from
the most- and least-deprived CCGs.20,21
All data were extracted, independently checked for accuracies
and analysed using Microsoft Excel, SPSS V21 and Stata V16.
3 | RESULTS
3.1 | Prescribing of antidementia drugs between
2009 and 2019
The number of prescription items dispensed in England for the phar-
macological treatment of dementia (antidementia drugs, BNF
Section 4.11) increased by approximately 3-fold (195.4%) from 24 pre-
scription items per 1000 population in 2009 to 70.9 prescription
items per 1000 population in 2019, reflecting an increase of 195.4%
(Table 1 and Figure 1).
TABLE 1 Prescription items and costs of all antidementia drugs (BNF Section 4.11) and antipsychotic drugs in England in 2009 and 2019
Prescription items per 1000
population, n (%)





Percentage (%) change in
cost 2009-20192009 2019 2009 2019 2009 2019
Antidementia drugs
Donepezila 15.37 (64.04) 36.88 (52.02) 1277.04 (64.39) 35.68 (8.70) 83.09 0.96 - 98.84
Rivastigminea 2.65 (11.04) 6.85 (9.66) 199.20 (10.45) 157.14 (38.33) 75.17 22.94 - 69.48
Galantaminea 4.90 (20.41) 2.94 (4.15) 350.95 (18.42) 90.74 (22.13) 71.62 30.86 - 56.91
Memantinea 1.08 (4.5) 24.6 (34.70) 78.57 (4.12) 127.09 (31.00) 72.75 5.17 - 92.89




31.81 (23.38) 36.00 (19.23) 421.10 (7.53) 301.79 (19.62)




160.06 258.11 7498.49 1948.17
Abbreviations: BNF, British National Formulary; GBP, Great British Pound.
aPercentage refers to proportion of all antidementia prescription items.
bPercentage refers to proportion of all antipsychotic prescription items.
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Donepezil was the most commonly prescribed antidementia drug
in both 2009 and 2019, accounting for 64.0% and 52.0% of all
antidementia prescriptions, respectively. Of all antidementia drugs,
the highest increase was noted for prescribing of memantine, which
increased from 4.5% in 2009 to 34.7% in 2019. Prescriptions for
galantamine decreased over the same period by 40% (Table 1).
The results presented an overall decrease in the cost incurred
from prescribing drugs for dementia, increasing by 17.5% from 2009
to 2011 but then drastically decreasing by 82.0% from 2011 to 2019.
This resulted in an overall decrease in costs of 81.7% from 2009 to
2019 (Table 1 and Figure 2).
The costs of prescribing rivastigmine peaked in 2012 at £342.69
per 1000 population, followed by a substantial reduction in costs by
88.8% in the following year between 2012 and 2013. Overall,
memantine costs increased by 61.8% from 2009 to 2019, peaking in
2013 at £434.54 per 1000 population. A significant reduction in the
costs of donepezil by 40.0% was observed between 2011 and 2012.
Donepezil's cost per item decreased by the largest proportion from
2019 to 2009, reducing by 98.8% over the 10 years (Table 1 and
Figure 2).
3.2 | Prescribing of antipsychotics drugs:
2009-2019
The prescribing of all antipsychotic drugs showed a steady increase
of 37.6% over the 10 years (Table 1 and Figure 3). Antipsychotic
prescribing was consistently higher than prescribing of antidementia
drugs, however, the rate of increase in prescribing for antidementia
drugs was higher during the study period. In particular, haloperidol
and risperidone prescriptions increased from 2009 to 2019 by
13.2% (Table 1 and Figure 3). Costs of prescribing all antipsychotic
drugs decreased by 71.4% from 2009 to 2019 (Table 1 and
Supporting Information Figure S1). Both antipsychotics and
antidementia drugs presented an initial increase in costs from 2009
to 2011, followed by a decrease from 2011 to 2016. Haloperidol
and risperidone showed a reduction in costs from £421.10 to
£301.79 (−28.33%) per 1000 population from 2009 to 2019
(Supporting Information Figure S1).
The proportion of patients with diagnosed dementia who were
prescribed an antipsychotic drug in the last 6 weeks of 2019 ranged
F IGURE 1 Prescription items of all
antidementia drugs (British National Formulary
Section 4.11) per 1000 population in England
from 2009 to 2019
F IGURE 2 Costs of prescribing for all antidementia drugs (British
National Formulary Section 4.11) per 1000 population in England
from 2009 to 2019, adjusted for inflation
F IGURE 3 Prescription items for antidementia drugs (British
National Formulary Section 4.11) and all antipsychotic drugs per 1000
population in England from 2009 to 2019
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from 6.99% to 15.54% within the 20 CCGs. The proportion of demen-
tia patients who were prescribed antipsychotic drugs without a psy-
chosis diagnosis ranged from 4.88% to 12.52% (Table 3).
3.3 | Association between deprivation and
prescribing
Prescribing in the least-deprived areas was substantially higher than
that in the most-deprived areas from 2015 to 2019 (Table 2). The
median (IQR) prescription items for the least deprived areas for all
five observations was 75.68 (72.32-86.67) compared with 44.62
(43.03-44.85) items per 1000 population in the most deprived
areas (P = .008). Similarly, the median (IQR) costs of prescribing
per 1000 population in the most-deprived areas across all five
observations were £255.18 (233.48-320.74) compared with
£625.87 (563.25-654.78) in the least-deprived areas (P = .008)
(Table 2). There was a larger observed variation in both items and
cost data within the most-deprived areas compared to the least-
deprived areas (Table 2). In the multivariable analysis, the prescrip-
tion items per 1000 population showed an inverse relationship
with deprivation after adjustment with population 65+ years and
prevalence of dementia (coefficient −0.046, 95% CI −0.47 to
−0.045, P < .001] (Supporting Information Table S2).
3.4 | Variations across NHS England
commissioning regions
Prescription items for dementia increased from 2015 to 2019 in every
NHS England commissioning region (Supporting Information
Table S3). Prescribing was consistently highest in the North-East and
Yorkshire region and lowest in the Midlands for the measured time
period. In 2009, 85.6 prescription items per 1000 population were
prescribed in the North-East and Yorkshire region compared with
41.2 per 1000 population in the Midlands. Similarly, in 2019, the
North-East and Yorkshire region prescribed 101.4 items per 1000
population, 96% higher than the 51.8 items prescribed in the Mid-
lands (P = .015). A significant difference in the median costs of pre-
scribing across the regions was also observed (P = .001).
4 | DISCUSSION
This overall aim of this study was to examine prescribing trends and
associated costs of antidementia drugs in primary care in England and
to investigate the impact of deprivation, regional demography and dis-
ease prevalence on prescribing practices and patient access to these
drugs. This study demonstrated a 3-fold rise in prescribing of
antidementia drugs in England in the last 10 years. The increase is
reflective of the policy emphases on the early and better diagnosis
and management of dementia in primary care in England. AD and
other dementias currently rank as the leading and second most com-
mon causes of death amongst females and males in England, respec-
tively.22 In 2011 and 2014, there were updates to the coding
framework in primary care used to code the cause of death. These
changes also required dementia to be identified as the underlying
cause of death rather than “other health conditions”. An updated
national strategy was launched in England, in 2020 which aimed to
continue to emphasise early diagnoses, treatment and support for
investigation and provision of newer therapies.23 The prescription
data analysed in this study triangulate well with the increasing preva-
lence and mortality data.
The number of prescription items for the NMDA receptor antago-
nist memantine presented the largest percentage increase over the
10 years. This notable increase emerged in 2011 and may be causally
linked with an update to the NICE guidelines in the same year. Prior
to 2011, memantine was only recommended for use in clinical trials
for patients with moderate to severe AD.24 However, following the
NICE guideline update, memantine was recommended for patients
TABLE 2 Prescription items and costs of antidementia drugs (BNF Section 4.11) in the 10 most- and 10 least-deprived CCGs in England per
1000 population from 2015 to 2019
Prescription items per 1000 population
median (IQR)
Inflation adjusted costs, GBP per 1000 population
median (IQR)
Most deprived Least deprived Most deprived Least deprived
Year, na
2015 43.24 (32.99-59.53) 70.28 (63.51-76.06) 367.21 (166.61-470.95) 688.03 (623.80-784.88)
2016 45.45 (37.20-65.32) 74.36 (66.18-82.19) 335.18 (149.71-453.13) 650.57 (529.58-716.50)
2017 45.63 (38.58-68.42) 77.27 (69.56-85.29) 279.52 (140.16-393.67) 551.49 (540.57-657.57)
2018 45.79 (37.81-65.70) 82.11 (75.57-86.70) 271.74 (133.09-341.85) 581.75 (438.52-634.60)
2019 46.65 (36.63-64.76) 91.23 (76.18-95.13) 310.2 (116.36-344.07) 666.4 (515.08-787.68)
Percentage (%) median change
from 2015 to 2019
7.88 29.81 −15.53 −3.14
Median all years 44.62 (43.03-44.85) 75.68 (72.32-86.67) 255.18 (233.48-320.74) 625.87 (563.25-654.78)
BNF, British National Formulary; CCG, clinical commissioning group; GBP, Great British Pound; IQR, inter-quartile range
an = sum of prescriptions and costs for 10 CCGs for each year per 1000 population.
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with moderate to severe AD who had a contraindication to AChE
inhibitors.25 This increase in memantine prescribing in 2011 is concur-
rent with the trends observed in another study.26
From 2009 to 2019, the cost per item of all antidementia drugs
(BNF Section 4.11) decreased by over 50%. Donepezil and memantine
saw the largest reduction in value, decreasing by 98.8% and 92.9%
respectively. The observed reduction in costs coincides with gal-
antamine's patent in January 2012, donepezil's in February 2012 and
rivastigmine's in July 2012. Memantine, the NMDA receptor antago-
nist, lost exclusivity in April of 2014.
Analysis at CCG level found an inverse relationship between dep-
rivation and prescribing patterns. This is concurrent with previous
findings reporting that in English practices, patients with dementia are
27% more likely to receive a dementia prescription in the least-
deprived areas than those in the most-deprived areas.27 The differ-
ences in the number of prescription items for antidementia drugs
were evident even after adjusting for the number of population aged
65 years and over and dementia prevalence. Therefore, further inves-
tigation is required to establish factors that might be contributing to
the disparities in access to antidementia drugs. There is a lack of
studies in the UK investigating factors that relate to such differential
prescribing rates. Data from international literature and under-
representative UK studies suggest that patients of minority ethnicity,
younger age during diagnosis and those with fewer academic qualifi-
cations are less likely to be prescribed antidementia drugs.28–31 There
is a need for clinical guidelines to emphasise early diagnosis and equi-
table access to dementia drugs. Qualitative study of prescribers,
patients and/or carers is needed. Patients with diagnosed dementia
are often residents of care homes, and therefore future interventions
to improve practice also need to focus on residential care settings.
The variations in prescribing rates were higher in the most-
deprived regions compared to the least-deprived regions. Regional
variations in prescribing rates were also observed with no clear-cut
north-south divide observed in the datasets. The data are suggestive
of the presence of pockets of “deprivation” and “affluence” in all
regions.32,33 These differences need to be investigated further.
This study also shows that the prescription of all antipsychotic
medication increased during the 10-year study period. As shown in
our data, the proportion of dementia patients prescribed antipsychotic
drugs without a confirmed diagnosis of psychosis ranged from 4.0 to
12.5%. The NDS, published in 2009, aimed to reduce antipsychotic
use among people with dementia. However, the trends in prescribing
antipsychotics from 2009 to 2019 have not reflected a change in pre-
scribing practices.4,34 Previous studies which looked into prescribing
of antipsychotics following the launch of the NDS also suggested no
notable change in prescribing rates 4 years after the implementation
of this strategy.6
5 | STRENGTHS AND LIMITATIONS
National prescribing datasets covering all patients registered with a
general practice in England were included in this study. We did not
investigate the record of the indications, reasons or length of treat-
ment for the drugs prescribed. Furthermore, the 10 most- and
10 least-deprived CCGs are only representatives of the two extremes,
and they do not represent the entire population of England. It is
important to note that the data regarding the prescriptions and costs
of antipsychotics were not exclusively related to prescribing for
dementia. Antipsychotics can be used to treat multiple other disor-
ders, such as psychosis, schizophrenia, bipolar disorder and major
depression, and other off-label uses.35,36 However, dementia is the
only condition where AChE inhibitors are prescribed.16 The available
prescription data analysed in this study related to all active patients in
the primary care medical records. Records of any patients who died
during the study period are not available.
6 | IMPLICATIONS FOR PRACTICE AND
RESEARCH
Quality, appropriateness and off-label prescribing of drugs for dementia
treatment need to be investigated in light of the rising trends in the
data. With a greater emphasis on diagnosis and treatment in primary
care, evaluations of prescriber behaviours, expertise and skills are
important to ensure that prescribing is evidence-based. The deprivation
level differences in rates of prescribing need to be investigated further.
In addition, wide variations in the rate of prescribing within the most-
deprived areas warrant further investigation. The continued rising trend
observed for prescribing of antipsychotic drugs requires further
research to identify the contribution of dementia to the observed trend.
7 | CONCLUSIONS
In the last 10 years there has been a nearly 3-fold rise in the number
of prescription items for antidementia drugs. The rising trend in pri-
mary care prescribing demonstrates greater participation of the sector
in the diagnosis and treatment of dementia and specialist psychiatry
care. The least-deprived regions have a prescribing rate that is approx-
imately twice as high as that in the most-deprived regions. Higher
rates of prescribing in the least-deprived areas may reflect better and
early diagnoses and access to treatment than offered in the most-
deprived areas. Such differences in access to treatments need to be
investigated further.
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